{"disease":{"id":"age-related-macular-degeneration-amd","name":"age related macular degeneration amd"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05146687","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","phase":"","overall_status":"COMPLETED","enrollment_count":369600,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05110209","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","phase":"","overall_status":"COMPLETED","enrollment_count":331541,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05066685","title":"Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program","phase":"","overall_status":"COMPLETED","enrollment_count":18457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05037396","title":"Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab","phase":"","overall_status":"COMPLETED","enrollment_count":9457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05082415","title":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)","phase":"","overall_status":"COMPLETED","enrollment_count":9456,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05111743","title":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)","phase":"","overall_status":"COMPLETED","enrollment_count":9261,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07069647","title":"Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics","phase":"NA","overall_status":"RECRUITING","enrollment_count":4300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06929143","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06075147","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07249307","title":"High-throughput Large-model-based AI-assisted Diagnosis Using OCT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07084883","title":"Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":1076,"lead_sponsor_name":"iHealthScreen Inc","has_results":false},{"nct_id":"NCT06843499","title":"Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06541704","title":"A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":975,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07516132","title":"Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":false},{"nct_id":"NCT06890026","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03349801","title":"Development of Novel Clinical Endpoints in Intermediate AMD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":718,"lead_sponsor_name":"Frank G. Holz","has_results":false},{"nct_id":"NCT00647439","title":"Genetics and Markers of Degenerative and Inflammatory Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03577041","title":"Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT04270747","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04543331","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04657289","title":"A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":451,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01972789","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06856577","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT07482176","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT06795048","title":"A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":274,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05481827","title":"ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":225,"lead_sponsor_name":"Gyroscope Therapeutics Limited","has_results":false},{"nct_id":"NCT03690505","title":"Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT07185841","title":"Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Fujian Haixi Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06116890","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT07365371","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07205887","title":"A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT01542866","title":"A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02348359","title":"X-82 to Treat Age-related Macular Degeneration","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":157,"lead_sponsor_name":"Tyrogenex","has_results":true},{"nct_id":"NCT07515521","title":"Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Maximilian Pfau","has_results":false},{"nct_id":"NCT05269966","title":"Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07206654","title":"Prevalence and Determinants of Shoulder Girdle Musculoskeletal Complaints in Geriatric Patients With Diminished Vision","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT06817915","title":"This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Johannes Schiefelbein","has_results":false},{"nct_id":"NCT02585401","title":"Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04292080","title":"Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04764656","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal","phase":"","overall_status":"TERMINATED","enrollment_count":81,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05932069","title":"Active AMD Study to Improve Function in Veterans","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07434713","title":"EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT07406438","title":"To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Shenzhen Kexing Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06908161","title":"Functional Assessments in Vision Impairment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Center for Eye Research Australia","has_results":false},{"nct_id":"NCT07164378","title":"International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"VisionCare, Inc.","has_results":false},{"nct_id":"NCT06839339","title":"Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Beijing Anlong Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07121127","title":"Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Zhiming Yan","has_results":false},{"nct_id":"NCT06664502","title":"A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false},{"nct_id":"NCT05282004","title":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Sandoz","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}